Use_NN of_IN Egg_NP Yolk-Derived_NP Immunoglobulin_NP as_IN an_DT Alternative_NP to_TO Antibiotic_JJ Treatment_NP for_IN Control_NP of_IN Helicobacter_NP pylori_NNS Infection_NN The_DT present_JJ study_NN evaluated_VBD the_DT potential_JJ use_NN of_IN immunoglobulin_NN prepared_VBN from_IN the_DT egg_NN yolk_NN of_IN hens_NNS immunized_VBN with_IN Helicobacter_NP pylori_NNS (_( immunoglobulin_NN Y_NP [_SYM IgY]-Hp_NP )_) in_IN the_DT treatment_NN of_IN H._NP pylori_NNS infections_NNS ._SENT The_DT purity_NN of_IN our_PP$ purified_VBN IgY-Hp_NP was_VBD 91.3_CD %_NN ,_, with_IN a_DT yield_NN of_IN 9.4_CD mg_NN of_IN IgY_NP per_IN ml_NN of_IN egg_NN yolk_NN ._SENT The_DT titer_NN for_IN IgY-Hp_NP was_VBD 16_CD times_NNS higher_JJR than_IN that_DT for_IN IgY_NP in_IN egg_NN yolk_NN from_IN nonimmunized_JJ hens_NNS ,_, and_CC IgY-Hp_NP significantly_RB inhibited_VBD the_DT growth_NN and_CC urease_NN activity_NN of_IN H._NP pylori_NNS in_IN vitro_NN ._SENT Bacterial_JJ adhesion_NN on_IN AGS_NP cells_NNS was_VBD definitely_RB reduced_VBN by_IN preincubation_NN of_IN both_DT H._NP pylori_NNS (_( 108_CD CFU/ml_NN )_) and_CC 10_CD mg_NN of_IN IgY-Hp/ml_NP ._SENT In_IN Mongolian_JJ gerbil_NN models_NNS ,_, IgY-Hp_NP decreased_VBD H._NP pylori-induced_JJ gastric_JJ mucosal_JJ injury_NN as_IN determined_VBN by_IN the_DT degree_NN of_IN lymphocyte_NN and_CC neutrophil_JJ infiltration_NN ._SENT Therefore_RB ,_, in_IN this_DT experimental_JJ model_NN ,_, H._NP pylori-associated_JJ gastritis_NN could_MD be_VB successfully_RB treated_VBN by_IN orally_RB administered_VBN IgY-Hp_NP ._SENT The_DT immunological_JJ activity_NN of_IN IgY-Hp_NP stayed_VBD active_JJ at_IN 60C_JJ for_IN 10_CD min_NN ,_, suggesting_VBG that_IN pasteurization_NN can_MD be_VB applied_VBN to_TO sterilize_VB the_DT product_NN ._SENT Fortification_NN of_IN food_NN products_NNS with_IN this_DT immunoglobulin_NN would_MD significantly_RB decrease_VB the_DT H._NP pylori_NNS infection_NN ._SENT In_IN conclusion_NN ,_, the_DT IgY-Hp_NP obtained_VBD from_IN hens_NNS immunized_VBN by_IN H._NP pylori_NNS could_MD provide_VB a_DT novel_JJ alternative_JJ approach_NN to_TO treatment_NN of_IN H._NP pylori_NNS infection_NN ._SENT Helicobacter_NN pylori_NNS is_VBZ the_DT most_RBS common_JJ cause_NN of_IN gastritis_NN and_CC gastric_JJ ulcers_NNS and_CC plays_VBZ a_DT pivotal_JJ role_NN in_IN the_DT development_NN of_IN gastric_JJ carcinomas_NNS ._SENT Often_RB a_DT significant_JJ portion_NN of_IN those_DT infected_VBN do_VBP not_RB show_VB symptoms_NNS ,_, although_IN chronic_JJ infection_NN increases_VBZ the_DT risk_NN of_IN the_DT development_NN of_IN H._NP pylori-associated_JJ gastric_JJ disease_NN ._SENT There_EX have_VBP been_VBN tremendous_JJ efforts_NNS to_TO evaluate_VB numerous_JJ therapeutic_JJ regimens_NNS for_IN eradication_NN of_IN H._NP pylori_NNS infections_NNS ._SENT Successful_JJ treatment_NN of_IN H._NP pylori_NNS infections_NNS most_JJS often_RB employs_VBZ antibiotic_JJ therapy_NN ,_, consisting_VBG of_IN some_DT combination_NN of_IN metronidazole_NN ,_, amoxicillin_NP ,_, clarithromycin_NN ,_, and_CC either_DT bismuth_NN or_CC a_DT proton_NN pump_NN inhibitor_NN ._SENT However_RB ,_, antibiotic_JJ therapy_NN fails_VBZ in_IN 10_CD to_TO 15_CD %_NN of_IN cases_NNS due_JJ to_TO the_DT development_NN of_IN antibiotic_JJ resistance_NN ._SENT Increasing_VBG occurrence_NN of_IN antibiotic_JJ resistance_NN would_MD further_RBR complicate_VB the_DT treatment_NN of_IN H._NP pylori_NNS infections_NNS ._SENT Consequently_RB ,_, it_PP is_VBZ important_JJ to_TO seek_VB new_JJ therapies_NNS for_IN a_DT wider_JJR means_NNS of_IN treating_VBG ,_, suppressing_VBG ,_, or_CC preventing_VBG H._NP pylori_NNS infection_NN without_IN drug_NN resistance_NN problems_NNS ._SENT The_DT concept_NN of_IN protecting_VBG a_DT host_NN with_IN passively_RB derived_VBN antibodies_NNS is_VBZ not_RB new_JJ ._SENT It_PP has_VBZ been_VBN shown_VBN that_IN oral_JJ administration_NN of_IN antibacterial_NN or_CC antiviral_JJ immunoglobulins_NNS ,_, through_IN infant_JJ formulae_NNS or_CC other_JJ diet_NN ,_, is_VBZ effective_JJ in_IN preventing_VBG intestinal_JJ infection_NN ._SENT However_RB ,_, oral_JJ administration_NN of_IN antibodies_NNS is_VBZ prohibitively_RB expensive_JJ when_WRB large_JJ amounts_NNS of_IN antibodies_NNS are_VBP required_VBN ._SENT Recently_RB ,_, chicken_NN egg_NN yolk_NN was_VBD recognized_VBN as_IN an_DT inexpensive_JJ ,_, alternative_JJ antibody_NN source_NN ,_, and_CC the_DT usefulness_NN of_IN egg_NN yolk_NN immunoglobulin_NN Y_NP (_( IgY_NP )_) has_VBZ been_VBN assessed_VBN for_IN therapeutic_JJ application_NN by_IN passive_JJ immunization_NN therapy_NN through_IN oral_JJ ingestion_NN of_IN IgY_NP ,_, as_RB in_IN fortified_VBN food_NN products_NNS for_IN prevention_NN or_CC control_NN of_IN intestinal_JJ infections_NNS ,_, such_JJ as_IN those_DT caused_VBN by_IN enterotoxigenic_JJ Escherichia_NP coli_NNS ,_, Salmonella_NP enterica_NP serovar_NP Typhimurium_NP ,_, and_CC rotavirus_NN ._SENT These_DT studies_NNS ,_, taken_VBN together_RB ,_, provide_VBP the_DT potential_JJ advantage_NN of_IN using_VBG IgY_NP with_IN specificity_NN to_TO H._NP pylori_NNS (_( IgY-Hp_NP )_) for_IN controlling_VBG H._NP pylori-associated_JJ gastric_JJ disease_NN and_CC subsequently_RB prevent_VB disease_NN resulting_VBG from_IN chronic_JJ infection_NN ._SENT Nevertheless_RB ,_, there_EX has_VBZ been_VBN no_DT report_NN so_RB far_RB on_IN the_DT use_NN of_IN IgY_NP in_IN the_DT prevention_NN and_CC treatment_NN of_IN H._NP pylori_NNS infections_NNS ._SENT Furthermore_RB ,_, for_IN the_DT practical_JJ application_NN of_IN IgY-Hp_NP ,_, together_RB with_IN food_NN or_CC pharmaceutical_JJ materials_NNS to_TO prevent_VB H._NP pylori-associated_JJ disease_NN ,_, the_DT stability_NN of_IN IgY_NP toward_IN heat_NN ,_, acid_NN ,_, and_CC pepsin_NN should_MD be_VB ensured_VBN ._SENT The_DT aim_NN of_IN this_DT study_NN was_VBD to_TO evaluate_VB the_DT potential_JJ use_NN of_IN IgY-Hp_NP in_IN the_DT prevention_NN and_CC treatment_NN of_IN H._NP pylori_NNS infections_NNS ._SENT To_TO achieve_VB this_DT objective_NN ,_, we_PP studied_VBD ,_, in_IN vitro_NN and_CC in_IN vivo_RB ,_, the_DT activity_NN of_IN IgY-Hp_NP against_IN H._NP pylori_NNS ._SENT The_DT effect_NN of_IN IgY-Hp_NP on_IN gastric_JJ mucosal_JJ injury_NN induced_VBN by_IN H._NP pylori_NNS was_VBD evaluated_VBN in_IN vivo_RB using_VBG Mongolian_JJ gerbils_NNS ._SENT The_DT stability_NN of_IN IgY-Hp_NP was_VBD also_RB investigated_VBN ._SENT H._NP pylori_NNS preparation_NN and_CC immunization_NN ._SENT |_SYM H._NP pylori_NNS (_( ATCC_NP 43504_CD )_) was_VBD cultured_VBN in_IN brucella_NN broth_NN (_( Difco_NP Laboratories_NP ,_, Detroit_NP ,_, Mich._NP )_) ,_, supplemented_VBN with_IN 5_CD %_NN (_( vol/vol_NN )_) bovine_JJ calf_NN serum_NN (_( PAA_NP Laboratories_NPS Inc._NP ,_, Parker_NP Ford_NP ,_, Pa._NP )_) and_CC antibiotics_NNS (_( amphotericin_NP B_NP ,_, 2.5_CD mug/ml_NN ;_: vancomycin_NP ,_, 10_CD mug/ml_NN ;_: trimethoprim_NP ,_, 5_CD mug/ml_NN ;_: and_CC polymyxin_NN B_NN ,_, 2.5_CD IU/ml_NN ;_: all_DT were_VBD from_IN Sigma_NP Chemical_NP Co._NP [_SYM St._NP Louis_NP ,_, Mo._NP ]_SYM )_) at_IN 37C_JJ under_IN 10_CD %_NN CO2_NN at_IN 200_CD rpm_NN ._SENT The_DT H._NP pylori_NNS was_VBD harvested_VBN by_IN centrifugation_NN at_IN 12,000_CD x_NN g_NN for_IN 10_CD min_NN and_CC disrupted_VBN by_IN sonication_NN ._SENT Cellular_JJ material_NN was_VBD removed_VBN by_IN centrifugation_NN ,_, and_CC the_DT supernatant_JJ was_VBD collected_VBN (_( H._NP pylori_NNS whole-cell_NN lysate_NN )_) ._SENT The_DT protein_NN concentrations_NNS were_VBD determined_VBN by_IN bicinchoninic_JJ acid_JJ methods_NNS (_( Pierce_NP ,_, Rockford_NP ,_, Ill._NP )_) ._SENT Brown_NP Leghorn_NP hens_NNS (_( 25_CD weeks_NNS old_JJ ;_: n_NN =_SYM 15_CD )_) were_VBD immunized_VBN intramuscularly_RB with_IN H._NP pylori_NNS whole-cell_NN lysate_NNS (_( 200_CD mug/ml_NN ,_, protein_NN )_) using_VBG an_DT equal_JJ volume_NN of_IN Freund_NP 's_POS complete_JJ adjuvant_NN (_( Difco_NP Laboratories_NPS )_) ._SENT Each_DT hen_NN was_VBD injected_VBN at_IN four_CD different_JJ sites_NNS (_( 250_CD mul_NN per_IN site_NN )_) of_IN the_DT leg_NN muscle_NN ._SENT Three_CD booster_NN injections_NNS ,_, with_IN Freund_NP 's_POS incomplete_JJ adjuvant_NN ,_, were_VBD given_VBN at_IN 2-week_JJ intervals_NNS following_VBG the_DT first_JJ injection_NN ._SENT One_CD month_NN after_IN immunization_NN ,_, the_DT eggs_NNS laid_VBN were_VBD collected_VBN daily_RB for_IN 1_CD month_NN and_CC stored_VBN at_IN 4C_JJ ._SENT The_DT egg_NN yolk_NN was_VBD separated_VBN ,_, pooled_VBN ,_, and_CC frozen_VBN prior_RB to_TO purification_NN of_IN IgY_NP ._SENT Isolation_NN and_CC purification_NN of_IN IgY-Hp_NP ._SENT |_SYM Isolation_NN of_IN IgY-Hp_NP was_VBD carried_VBN out_RP by_IN the_DT method_NN described_VBN by_IN Akita_NP and_CC Nakai_NP with_IN modification_NN ._SENT Egg_NN yolk_NN was_VBD separated_VBN from_IN the_DT white_JJ ,_, and_CC the_DT yolk_NN preparation_NN was_VBD mixed_VBN with_IN an_DT equal_JJ volume_NN of_IN distilled_JJ water_NN for_IN 30_CD min_NN ,_, followed_VBN by_IN the_DT addition_NN of_IN 0.15_CD %_NN (_( wt/vol_NN )_) lambda-carrageenan_NP (_( Wako_NP Pure_NP Chemical_NP Laboratory_NP ,_, Osaka_NP ,_, Japan_NP )_) ._SENT After_IN centrifugation_NN at_IN 10,000_CD x_NN g_NN at_IN 20C_JJ for_IN 30_CD min_NN ,_, the_DT water-soluble_JJ fraction_NN (_( WSF_NP )_) was_VBD collected_VBN and_CC filtered_VBN through_IN a_DT Whatman_NP filter_NN paper_NN (_( no_UH ._SENT 1_LS )_) to_TO remove_VB solid_JJ lipid_NN materials_NNS ._SENT The_DT resulting_JJ IgY-containing_NP filtrate_NN was_VBD further_RBR purified_VBN by_IN salt_NN precipitation_NN (_( 19_CD %_NN [_SYM wt/vol_NN ]_SYM sodium_NN sulfate_NN )_) and_CC ultrafiltration_NN (_( UF_NP )_) using_VBG a_DT UF_NP membrane_NN (_( Millipore_NP Corp._NP ,_, Bedford_NP ,_, Mass._NP )_) cartridge_NN with_IN a_DT molecular_JJ weight_NN cutoff_NN of_IN 100_CD kDa_NN ._SENT Purity_NN and_CC yield_NN of_IN IgY_NP were_VBD monitored_VBN at_IN various_JJ stages_NNS by_IN sodium_NN dodecyl_NN sulfate-polyacrylamide_NN gel_NN electrophoresis_NN (_( SDS-PAGE_NP )_) ._SENT The_DT IgY_NP content_NN was_VBD measured_VBN by_IN its_PP$ absorbance_NN at_IN 280_CD nm_NN ._SENT SDS-PAGE_NP ._SENT |_SYM According_VBG to_TO the_DT method_NN of_IN Laemmli_NP ,_, 10_CD %_NN PAGE_NN was_VBD done_VBN with_IN a_DT Mini-PROTEAN_NP II_NP Cell_NP (_( Bio-Rad_NP Laboratories_NP ,_, Hercules_NP ,_, Calif._NP )_) ._SENT Under_IN nonreducing_NN conditions_NNS ,_, samples_NNS were_VBD diluted_VBN 1:4_CD with_IN sample_NN buffer_NN (_( 62.6_CD mM_NP Tris-HCl_NP ,_, pH_NN 6.8_CD ,_, 25_CD %_NN [_SYM vol/vol_NN ]_SYM glycerol_NN ,_, and_CC 2_CD %_NN SDS_NP [_SYM vol/vol_NN ]_SYM )_) ._SENT Under_IN reducing_VBG conditions_NNS ,_, samples_NNS were_VBD diluted_VBN with_IN sample_NN buffer_NN containing_VBG 5_CD %_NN (_( vol/vol_NN )_) beta-mercaptoethanol_NN and_CC heated_VBN for_IN 5_CD min_NN at_IN 100C_NP ._SENT Fifteen_CD microliters_NNS of_IN the_DT samples_NNS was_VBD loaded_VBN into_IN each_DT well_RB (_( 3_CD mug_NN of_IN protein_NN per_IN well_RB )_) ._SENT Prestained_NP SDS-PAGE_NP standards_NNS (_( Bio-Rad_NP Laboratories_NPS )_) and_CC standard_JJ chicken_NN IgY_NP (_( Promega_NP ,_, Madison_NP ,_, Wis._NP )_) were_VBD used_VBN as_IN molecular_JJ weight_NN markers_NNS ._SENT ELISA_NP ._SENT |_SYM To_TO assess_VB the_DT antibody_NN activity_NN of_IN IgY-Hp_NP to_TO H._NP pylori_NNS ,_, we_PP performed_VBD the_DT enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) by_IN Akita_NP et_FW al._FW with_IN modification_NN ._SENT Ninety-six-well_NP plates_NNS were_VBD coated_VBN with_IN H._NP pylori_NNS whole-cell_NN lysate_NNS (_( 500_CD ng/well_NNS )_) ._SENT After_IN blocking_VBG with_IN 1_CD %_NN (_( wt/vol_NN )_) bovine_JJ serum_NN albumin_NN ,_, 100_CD mul_NN of_IN IgY-Hp_NP (_( 1_CD mg/ml_NN )_) was_VBD added_VBN using_VBG a_DT twofold_JJ serial_JJ dilution_NN ._SENT The_DT plates_NNS were_VBD then_RB washed_VBN with_IN phosphate-buffered_JJ saline_JJ (PBS)-Tween_NNS (_( 0.05_CD %_NN Tween_NP 20_CD in_IN PBS_NP [_SYM pH_NN 7.2_CD ]_SYM )_) and_CC incubated_VBN for_IN 1_CD h_NN after_IN the_DT addition_NN of_IN alkaline_JJ phosphatase-conjugated_JJ goat_NN anti-chicken_NP IgY_NP (_( Promega_NP )_) ._SENT The_DT plates_NNS were_VBD washed_VBN with_IN PBS-Tween_NP ,_, and_CC disodium_NN p-nitrophenyl_NN phosphate_NN (_( Sigma_NP )_) was_VBD added_VBN as_IN substrate_NN to_TO each_DT well_NN ._SENT After_IN incubation_NN for_IN 10_CD min_NN ,_, the_DT reaction_NN was_VBD stopped_VBN by_IN addition_NN of_IN 3_CD M_NP NaOH_NP ._SENT The_DT absorbance_NN was_VBD measured_VBN at_IN 405_CD nm_NN using_VBG a_DT microplate_NN reader_NN (_( Multiskan_NP MS_NP ;_: Thermo_NP Labsystems_NP ,_, Helsinki_NP ,_, Finland_NP )_) ._SENT Heat_NN ,_, acid_NN ,_, and_CC pepsin_NN stability_NN of_IN IgY-Hp_NP ._SENT |_SYM IgY-Hp_NP solutions_NNS were_VBD incubated_VBN at_IN 0_CD ,_, 4_CD ,_, 10_CD ,_, 25_CD ,_, 35_CD ,_, 60_CD ,_, 70_CD ,_, 80_CD ,_, and_CC 90C_NN for_IN 10_CD min_NN ._SENT The_DT heat-treated_VBN IgY-Hp_NP was_VBD cooled_VBN in_IN an_DT ice_NN bath_NN ._SENT For_IN the_DT pH_NN stability_NN test_NN ,_, the_DT pHs_NNS of_IN IgY-Hp_NP solutions_NNS were_VBD adjusted_VBN to_TO the_DT desired_VBN pH_NN (_( pH_NN 2_CD to_TO 8_CD )_) with_IN NaOH_NP or_CC HCl_NP ,_, the_DT solutions_NNS were_VBD incubated_VBN at_IN 37C_JJ for_IN 4_CD h_NN ,_, and_CC then_RB each_DT IgY-Hp_NP solution_NN was_VBD neutralized_VBN ._SENT For_IN the_DT pepsin_NN stability_NN tests_NNS ,_, the_DT pHs_NNS of_IN the_DT IgY-Hp_NP solutions_NNS were_VBD adjusted_VBN to_TO pH_NN 2_CD ,_, pH_NN 4_CD ,_, and_CC pH_NN 6_CD ,_, respectively_RB ._SENT IgY-Hp_NN solution_NN of_IN each_DT pH_NN were_VBD incubated_VBN with_IN 15_CD mug_NN of_IN pepsin_NN (Sigma)/ml_NN at_IN 37C_JJ for_IN 0.5_CD ,_, 1_CD ,_, 2_CD ,_, and_CC 4_CD h._NN After_IN incubation_NN ,_, each_DT IgY-Hp_NP solution_NN was_VBD neutralized_VBN to_TO inactivate_VB the_DT pepsin_NN ._SENT The_DT remaining_VBG antibody_NN activity_NN was_VBD measured_VBN by_IN ELISA_NP ,_, following_VBG the_DT heat_NN ,_, pH_NN ,_, and_CC pepsin_NN treatments_NNS ._SENT Antibody_NN activity_NN was_VBD represented_VBN as_IN a_DT percentage_NN of_IN control_NN ._SENT Colony_NN counting_NN ._SENT |_SYM H._NP pylori_NNS (_( 108_CD CFU/ml_NP )_) was_VBD incubated_VBN with_IN IgY-Hp_NP (_( 1_CD and_CC 10_CD mg/ml_NN )_) for_IN 6_CD h_NN at_IN 37oC_JJ under_IN 10_CD %_NN CO2_NN at_IN 50_CD rpm_NN ._SENT After_IN incubation_NN ,_, H._NP pylori_NNS was_VBD diluted_VBN with_IN brucella_NN broth_NN via_IN a_DT 10-fold_NN series_NN dilution_NN ._SENT Each_DT 100_CD mul_NN was_VBD inoculated_VBN onto_IN brucella_NN agar_NN containing_VBG 5_CD %_NN (_( vol/vol_NN )_) bovine_JJ calf_NN serum_NN ,_, and_CC the_DT plate_NN contents_NNS were_VBD incubated_VBN at_IN 37C_JJ under_IN 10_CD %_NN CO2_NN for_IN 10_CD days_NNS ._SENT The_DT colonies_NNS were_VBD identified_VBN as_IN H._NP pylori_NNS by_IN Gram_NP staining_VBG and_CC urease_NN ,_, oxidase_NN ,_, and_CC catalase_NN activities_NNS ._SENT The_DT growth_NN rate_NN (_( percentage_NN of_IN control_NN )_) was_VBD calculated_VBN by_IN colony_NN counting_NN compared_VBN to_TO results_NNS for_IN the_DT control_NN ._SENT Urease_NN activities_NNS ._SENT |_SYM Both_NP IgY-Hp_NP (_( 1_CD and_CC 10_CD mg/ml_NN )_) and_CC H._NP pylori_NNS (_( 108_CD CFU/ml_NP )_) were_VBD incubated_VBN at_IN 37C_JJ under_IN 10_CD %_NN CO2_NN for_IN 6_CD h_NN at_IN 50_CD rpm_NN ,_, and_CC then_RB 50_CD mul_NN of_IN urea_NN base_NN (_( 2_CD %_NN urea_NN and_CC 0.03_CD %_NN phenol_NN red_NN )_) was_VBD added_VBN and_CC allowed_VBN to_TO react_VB for_IN 30_CD min_NN ._SENT Urease_NN activity_NN was_VBD quantified_VBN by_IN measuring_VBG the_DT optical_JJ density_NN at_IN 550_CD nm_NN ,_, using_VBG a_DT modification_NN to_TO the_DT method_NN of_IN Fauchere_NP and_CC Blaser_NP ,_, and_CC was_VBD represented_VBN as_IN %_NN of_IN control_NN ._SENT H._NP pylori_NNS adhesion_NN on_IN AGS_NP cells_NNS ._SENT |_SYM The_DT human_JJ gastric_JJ carcinoma_NN cell_NN line_NN AGS_NP was_VBD obtained_VBN from_IN the_DT Korean_JJ Cell_NP Line_NP Bank_NP (_( Seoul_NP ,_, Korea_NP )_) ._SENT Cells_NNS (_( 105_CD cells/ml_NN )_) were_VBD cultured_VBN in_IN RPMI_NP 1640_CD medium_NN (_( Gibco_NP BRL_NP ,_, Grand_NP Island_NP ,_, N.Y._NP )_) ,_, supplemented_VBN with_IN 10_CD %_NN (_( vol/vol_NN )_) fetal_JJ bovine_JJ serum_NN (_( HyClone_NP Laboratories_NP ,_, Logan_NP ,_, Utah_NP )_) and_CC antibiotics_NNS (_( 100_CD U_NN of_IN penicillin/ml_NN and_CC 100_CD mug_NN of_IN streptomycin/ml_NN ;_: HyClone_NP )_) at_IN 37C_JJ under_IN 5_CD %_NN CO2_NN for_IN 24_CD h._JJ AGS_NP cells_NNS were_VBD checked_VBN for_IN their_PP$ H._NP pylori_NNS colonization_NN level_NN in_IN the_DT presence_NN or_CC absence_NN of_IN IgY-Hp_NP using_VBG scanning_VBG electron_NN microscopy_NN (_( SEM_NP )_) ._SENT SEM_NP ._SENT |_SYM For_IN electron_NN microscopy_NN investigation_NN of_IN bacterial_JJ adhesion_NN ,_, 300_CD mul_NN of_IN preincubated_JJ IgY-Hp_NP (_( 10_CD mg/ml_NN )_) and_CC H._NP pylori_NNS (_( 108_CD CFU/ml_NP )_) was_VBD added_VBN to_TO the_DT AGS_NP cells_NNS on_IN the_DT chamber_NN slide_NN (_( Nalge_NP Nunc_NP International_NP ,_, Naperville_NP ,_, Ill._NP )_) ._SENT After_IN incubation_NN for_IN 4_CD h_NN ,_, the_DT chamber_NN slide_NN was_VBD washed_VBN with_IN PBS_NP and_CC fixed_VBN with_IN 2.5_CD %_NN (_( vol/vol_NN )_) glutaraldehyde_NN for_IN 24_CD h._NN After_IN washing_NN with_IN PBS_NP ,_, the_DT material_NN was_VBD postfixed_VBN with_IN 1_CD %_NN OSO4_NN for_IN 60_CD min_NN and_CC then_RB washed_VBN twice_RB with_IN PBS_NP ._SENT Fixed_VBN material_NN was_VBD dehydrated_VBN through_IN a_DT graded_VBN ethanol_NN series_NN from_IN 50_CD to_TO 95_CD %_NN ,_, followed_VBN by_IN two_CD washes_VBZ with_IN absolute_JJ ethanol_NN for_IN 15_CD min_NN ._SENT Dehydrated_VBN material_NN ,_, in_IN absolute_JJ ethanol_NN ,_, was_VBD critical_JJ point_NN dried_VBN in_IN a_DT critical_JJ point_NN drier_NN (_( HCP-2_NP ;_: Hitachi_NP ,_, Tokyo_NP ,_, Japan_NP )_) ._SENT Critical_JJ point_NN dried_VBD material_NN was_VBD mounted_VBN on_IN an_DT aluminum_NN stub_NN and_CC coated_VBN with_IN gold_NN ._SENT Adherence_NN of_IN H._NP pylori_NNS to_TO AGS_NP cells_NNS was_VBD observed_VBN by_IN SEM_NP (_( S2500_NP ;_: Hitachi_NP )_) ._SENT Passive_JJ immunization_NN with_IN IgY-Hp_NP against_IN H._NP pylori_NNS infection_NN in_IN Mongolian_JJ gerbils_NNS ._SENT |_SYM Mongolian_JJ gerbils_NNS (_( 6-week-old_JJ males_NNS )_) were_VBD purchased_VBN from_IN Bio_NP Animal_NP 21_NP (_( Sung-Nam_NP ,_, Korea_NP )_) ._SENT The_DT gerbils_NNS were_VBD infected_VBN with_IN H._NP pylori_NNS (_( 0.5_CD ml_NN ,_, 108_CD CFU/ml_NP ,_, orally_RB )_) three_CD times_NNS at_IN 12-h_NP intervals_NNS ._SENT Two_CD weeks_NNS after_IN inoculation_NN ,_, immune_JJ response_NN to_TO infection_NN was_VBD monitored_VBN by_IN ELISA_NP ._SENT H._NP pylori-infected_JJ gerbils_NNS were_VBD randomly_RB divided_VBN into_IN three_CD groups_NNS as_RB follows_VBZ :_: (_( i_NP )_) H._NP pylori_NNS infection_NN only_RB (_( n_NN =_SYM 10_CD )_) ,_, (_( ii_NP )_) treatment_NN with_IN 1_CD mg_NN of_IN IgY-Hp_NP treatment/ml_NP (_( n_NN =_SYM 10_CD )_) ,_, and_CC (_( iii_NN )_) treatment_NN with_IN 10_CD mg_NN of_IN IgY-Hp/ml_NP (_( n_NN =_SYM 10_CD )_) ._SENT Negative_JJ control_NN groups_NNS were_VBD administered_VBN IgY-Hp_NP (_( 1_CD and_CC 10_CD mg/ml_NN )_) alone_RB (_( n_NN =_SYM 10_CD )_) ._SENT IgY-Hp_NP (_( 1_CD ml_NN )_) was_VBD administered_VBN daily_RB ,_, using_VBG an_DT oral_JJ feeding_NN needle_NN ,_, for_IN 4_CD weeks_NNS ._SENT After_IN the_DT gerbils_NNS were_VBD fasted_VBN for_IN 24_CD h_NN ,_, the_DT antral_JJ portion_NN of_IN stomach_NN was_VBD quickly_RB removed_VBN and_CC used_VBN for_IN histological_JJ examinations_NNS ._SENT Formalin-fixed_JJ tissue_NN was_VBD processed_VBN routinely_RB in_IN paraffin_NN and_CC stained_VBN with_IN hematoxylin_NN and_CC eosin_NN for_IN examination_NN by_IN light_JJ microscopy_NN ._SENT Gastric_JJ mucosal_JJ injury_NN was_VBD classified_VBN and_CC scored_VBN on_IN a_DT scale_NN of_IN 0_CD ,_, 1_CD ,_, 2_CD ,_, or_CC 3_CD ,_, according_VBG to_TO the_DT updated_VBN Sydney_NP system_NN ._SENT Statistical_JJ analysis_NN ._SENT |_SYM All_DT data_NNS were_VBD expressed_VBN as_IN the_DT means_NN +-_NN standard_JJ deviations_NNS (_( SD_NP )_) ._SENT The_DT statistical_JJ significance_NN was_VBD evaluated_VBN by_IN Student_NP 's_POS t_NN tests_NNS ._SENT P_NN values_NNS of_IN <0.05_NN were_VBD considered_VBN statistically_RB significant_JJ ._SENT Purification_NN and_CC characterization_NN of_IN IgY-Hp_NP from_IN egg_NN yolk_NN ._SENT |_SYM Isolation_NN of_IN egg_NN yolk_NN IgY_NP ,_, using_VBG the_DT lambda-carrageenan_JJ method_NN followed_VBN by_IN a_DT UF_NP system_NN ,_, was_VBD effective_JJ ._SENT The_DT purity_NN of_IN the_DT IgY_NP obtained_VBD was_VBD 91.3_CD %_NN ,_, with_IN a_DT yield_NN of_IN 9.4_CD mg_NN of_IN IgY_NP per_IN ml_NN of_IN egg_NN yolk_NN ._SENT The_DT egg_NN yolk_NN proteins_NNS obtained_VBN during_IN purification_NN of_IN IgY_NP were_VBD analyzed_VBN using_VBG SDS-PAGE_NP ._SENT As_IN shown_VBN in_IN Fig._NN ,_, the_DT IgY_NP finally_RB purified_VBD ,_, using_VBG the_DT UF_NP system_NN ,_, was_VBD pure_JJ and_CC dissociated_VBN into_IN heavy_JJ and_CC light_JJ chains_NNS of_IN 64_CD and_CC 25_CD kDa_NNS ,_, respectively_RB ._SENT The_DT electrophoretic_JJ patterns_NNS were_VBD in_IN perfect_JJ accordance_NN with_IN commercially_RB available_JJ IgY_NP (_( Promega_NP )_) (_( Fig._NN ,_, lane_NN 2_CD )_) ._SENT After_IN treating_VBG the_DT egg_NN yolk_NN with_IN lambda-carrageenan_NP ,_, the_DT number_NN of_IN proteins_NNS in_IN the_DT WSF_NP were_VBD significantly_RB decreased_VBN ._SENT These_DT contaminating_VBG proteins_NNS were_VBD removed_VBN by_IN salting_VBG out_RP with_IN 19_CD %_NN sodium_NN sulfate_NN ._SENT The_DT IgY_NP preparation_NN was_VBD concentrated_VBN and_CC desalted_VBN using_VBG the_DT UF_NP system_NN ._SENT The_DT IgY_NP and_CC IgY-Hp_NP obtained_VBD from_IN hens_NNS without_IN and_CC with_IN H._NP pylori_NNS immunization_NN ,_, respectively_RB ,_, were_VBD examined_VBN for_IN immunological_JJ properties_NNS by_IN ELISA_NP ._SENT The_DT ELISA_NP titers_NNS were_VBD 640_CD and_CC 10,240_CD for_IN IgY_NP and_CC IgY-Hp_NP ,_, respectively_RB ._SENT These_DT results_NNS indicate_VBP that_IN IgY-Hp_NP is_VBZ highly_RB specific_JJ to_TO H._NP pylori_NNS ._SENT The_DT heat_NN ,_, pH_NN ,_, and_CC pepsin_NN stabilities_NNS of_IN IgY-Hp_NP were_VBD evaluated_VBN by_IN ELISA_NP ._SENT The_DT IgY-Hp_NP was_VBD stable_JJ at_IN 40C_JJ ._SENT However_RB ,_, at_IN 60C_JJ for_IN 10_CD min_NN ,_, IgY-Hp_NP lost_VBD approximately_RB 20_CD %_NN of_IN its_PP$ antibody_NN activity_NN ._SENT The_DT antibody_NN activity_NN of_IN IgY-Hp_NP significantly_RB decreased_VBD at_IN 80C_JJ and_CC lost_VBD up_RP to_TO 90_CD %_NN of_IN its_PP$ activity_NN ._SENT IgY-Hp_NP showed_VBD broad_JJ stability_NN between_IN the_DT pHs_NNS 4_CD and_CC 8_CD ._SENT However_RB ,_, IgY-Hp_NP lost_VBD 80_CD and_CC 70_CD %_NN of_IN its_PP$ initial_JJ activity_NN at_IN pH_NN 2_CD and_CC 3_CD ,_, respectively_RB ._SENT The_DT antibody_NN activity_NN of_IN IgY-Hp_NP ,_, as_RB determined_VBN by_IN ELISA_NP ,_, was_VBD almost_RB lost_VBN when_WRB incubated_VBN with_IN pepsin_NN at_IN pH_NN 2_CD ,_, while_IN about_RB 92_CD and_CC 99_CD %_NN of_IN the_DT activity_NN remained_VBD at_IN pH_NN 4_CD and_CC 6_CD ,_, respectively_RB ._SENT Effects_NNS of_IN IgY-Hp_NP on_IN growth_NN and_CC urease_NN activity_NN of_IN H._NP pylori_NNS in_IN vitro_NN ._SENT |_SYM To_TO determine_VB the_DT effect_NN of_IN IgY-Hp_NP on_IN the_DT growth_NN and_CC urease_NN activity_NN of_IN H._NP pylori_NNS ,_, we_PP compared_VBD growth_NN rates_NNS and_CC urease_NN activity_NN with_IN those_DT of_IN the_DT control_NN ._SENT The_DT growth_NN rates_NNS for_IN H._NP pylori_NNS were_VBD 60.0_CD %_NN +-_NN 9.5_CD %_NN and_CC 10.0_CD %_NN +-_NN 10.8_CD %_NN compared_VBN with_IN those_DT found_VBN for_IN the_DT control_NN ,_, after_IN incubation_NN with_IN 1_CD mg_NN and_CC 10_CD mg_NN of_IN IgY-Hp/ml_NP ,_, respectively_RB ._SENT When_WRB H._NP pylori_NNS (_( 108_CD CFU/ml_NP )_) was_VBD incubated_VBN with_IN IgY-Hp_NP (_( 1_CD and_CC 10_CD mg/ml_NN )_) for_IN 6_CD h_NN ,_, the_DT urease_NN activity_NN of_IN H._NP pylori_NNS was_VBD 75.4_CD %_NN +-_NN 8.5_CD %_NN and_CC 15.5_CD %_NN +-_NN 7.4_CD %_NN compared_VBN with_IN that_DT of_IN the_DT control_NN ._SENT Effect_NN of_IN IgY-Hp_NP on_IN H._NP pylori-induced_JJ gastritis_NN in_IN the_DT Mongolian_JJ gerbils_NNS model_NN ._SENT |_SYM Mongolian_JJ gerbils_NNS were_VBD inoculated_VBN with_IN H._NP pylori_NNS ._SENT Two_CD weeks_NNS after_IN the_DT inoculation_NN ,_, the_DT status_NN of_IN infection_NN was_VBD confirmed_VBN by_IN measuring_VBG the_DT serum_NN antibody_NN (_( IgG_NP )_) against_IN H._NP pylori_NNS ._SENT The_DT H._NP pylori-infected_JJ gerbils_NNS were_VBD determined_VBN by_IN high_JJ IgG_NP titer_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Oral_JJ administration_NN of_IN 10_CD mg_NN of_IN IgY-Hp/ml_NP for_IN 4_CD weeks_NNS to_TO the_DT H._NP pylori-infected_JJ gerbils_NNS improved_VBD lymphocyte_NN infiltration_NN compared_VBN to_TO that_DT found_VBN for_IN the_DT H._NP pylori_NNS infection_NN group_NN with_IN no_DT IgY-Hp_NP (_( 1.2_CD +-_NN 0.8_CD versus_CC 2.5_CD +-_NN 0.5_CD ;_: P_NN <_SYM 0.01_CD )_) ._SENT However_RB ,_, the_DT group_NN that_WDT was_VBD administered_VBN 1_CD mg_NN of_IN IgY-Hp/ml_NP showed_VBD no_DT statistically_RB significant_JJ difference_NN with_IN the_DT H._NP pylori_NNS infection_NN group_NN (_( 2.4_CD +-_NN 1.1_CD versus_CC 2.5_CD +-_NN 0.5_CD )_) ._SENT The_DT group_NN treated_VBN with_IN 10_CD mg_NN of_IN IgY/ml_NP significantly_RB improved_VBD neutrophil_JJ infiltration_NN (_( 0.9_CD +-_NN 0.7_CD versus_CC 2.3_CD +-_NN 0.8_CD ;_: P_NN <_SYM 0.01_CD )_) ._SENT There_EX was_VBD no_DT statistically_RB significant_JJ difference_NN between_IN the_DT group_NN treated_VBN with_IN 1_CD mg_NN of_IN IgY-Hp/ml_NP and_CC the_DT H._NP pylori_NNS infection_NN group_NN (_( 2.2_CD +-_NN 0.5_CD versus_CC 2.3_CD +-_NN 0.8_CD )_) ._SENT A_DT high_JJ dose_NN of_IN IgY-Hp_NP treatment_NN decreased_VBD H._NP pylori-induced_JJ lymphocyte_NN and_CC neutrophil_JJ infiltration_NN in_IN gastric_JJ mucosa_NN ._SENT However_RB ,_, a_DT low_JJ dose_NN of_IN IgY_NP failed_VBD to_TO protect_VB gerbils_NNS from_IN H._NP pylori-induced_JJ gastric_JJ mucosal_JJ injury_NN ._SENT Effect_NN of_IN IgY-Hp_NP on_IN H._NP pylori_NNS attachment_NN on_IN AGS_NP cells_NNS ._SENT |_SYM Figure_NN shows_VBZ SEM_NP of_IN AGS_NP cells_NNS and_CC those_DT infected_JJ with_IN H._NP pylori_NNS (_( 108_CD CFU/ml_NN )_) in_IN the_DT presence_NN and_CC absence_NN of_IN IgY-Hp_NP (_( 10_CD mg/ml_NN )_) ._SENT Numerous_JJ rod-shaped_JJ H._NP pylori_NNS organisms_NNS ,_, attached_VBN to_TO the_DT AGS_NP cells_NNS '_POS surfaces_NNS ,_, were_VBD observed_VBN when_WRB cells_NNS were_VBD cultured_VBN with_IN H._NP pylori_NNS ._SENT On_IN the_DT other_JJ hand_NN ,_, the_DT number_NN of_IN adhering_VBG H._NP pylori_NNS organisms_NNS dramatically_RB decreased_VBD when_WRB cells_NNS were_VBD pretreated_VBN with_IN IgY-Hp_NP ._SENT FIG._NN 1_CD ._SENT |_SYM SDS-PAGE_NP patterns_NNS of_IN IgY_NP purified_VBD from_IN egg_NN yolk_NN ._SENT SDS-PAGE_NN patterns_NNS of_IN IgY_NP purified_VBD from_IN egg_NN yolk_NN ._SENT (_( A_NP )_) Coomassie-stained_NP SDS-10_NP %_NN PAGE_NN under_IN nonreducing_JJ conditions_NNS ._SENT (_( B_LS )_) Reducing_VBG conditions_NNS of_IN SDS-10_NP %_NN PAGE_NN ._SENT Lanes_NNS :_: 1_LS ,_, molecular_JJ size_NN marker_NN ,_, 2_CD ,_, chicken_NN IgY_NP ,_, standard_JJ immunoglobulin_NN (_( Promega_NP )_) ,_, 3_CD ,_, egg_NN yolk_NN ,_, 4_CD ,_, WSF_NP after_IN lambda-carrageenan_NP treatment_NN ,_, 5_CD ,_, IgY_NP obtained_VBD after_IN salting_VBG out_RP ,_, and_CC 6_CD ,_, final_JJ IgY_NP obtained_VBD by_IN UF_NP ._SENT FIG._NN 2_CD ._SENT |_SYM The_DT reaction_NN between_IN IgY-Hp_NP and_CC H._NP pylori_NNS The_DT reaction_NN between_IN IgY-Hp_NP and_CC H._NP pylori_NNS ._SENT One_CD hundred_CD microliters_NNS of_IN IgY-Hp_NP (_( 1_CD mg/ml_NN )_) was_VBD added_VBN with_IN a_DT twofold_JJ serial_JJ dilution_NN in_IN 96-well_NN plates_NNS coated_VBN with_IN H._NP pylori_NNS whole-cell_NN lysate_NNS (_( 500_CD ng/well_NNS )_) ,_, and_CC the_DT titers_NNS were_VBD measured_VBN using_VBG ELISA_NP ._SENT IgY_NP was_VBD isolated_VBN from_IN the_DT egg_NN yolk_NN of_IN nonimmunized_JJ hens_NNS ,_, and_CC IgY-Hp_NP was_VBD obtained_VBN from_IN H._NP pylori-immunized_JJ hens_NNS ._SENT FIG._NN 3_CD ._SENT |_SYM Heat_NP ,_, pH_NN ,_, and_CC pepsin_NN stability_NN of_IN IgY-Hp_NP ._SENT Heat_NN ,_, pH_NN ,_, and_CC pepsin_NN stability_NN of_IN IgY-Hp_NP ._SENT IgY-Hp_NP was_VBD treated_VBN at_IN various_JJ temperatures_NNS for_IN 10_CD min_NN (_( A_NP )_) ,_, at_IN various_JJ pHs_NNS for_IN 4_CD h_NN (_( B_NP )_) ,_, and_CC with_IN pepsin_NN (_( 15_CD mul/ml_NN )_) (_( C_NP )_) at_IN pH_NN 2_CD ,_, 4_CD ,_, and_CC 6_CD for_IN 0.5_CD ,_, 1_CD ,_, 2_CD ,_, and_CC 4_CD h._JJ Remaining_VBG activities_NNS after_IN the_DT treatments_NNS were_VBD measured_VBN using_VBG ELISA_NP and_CC are_VBP expressed_VBN as_IN a_DT percentage_NN of_IN the_DT initial_JJ activity_NN ._SENT FIG._NN 4_CD ._SENT |_SYM Effect_NN of_IN IgY-Hp_NP on_IN the_DT growth_NN and_CC urease_NN activity_NN of_IN H._NP pylori_NNS ._SENT H._NP pylori_NNS Effect_NN of_IN IgY-Hp_NP on_IN the_DT growth_NN and_CC urease_NN activity_NN of_IN H._NP pylori_NNS ._SENT H._NP pylori_NNS (_( 108_CD CFU/ml_NP )_) was_VBD incubated_VBN with_IN of_IN IgY-Hp_NP (_( 1_CD and_CC 10_CD mg/ml_NN )_) for_IN 6_CD h_NN at_IN 37C_JJ under_IN 10_CD %_NN CO2_NN at_IN 50_CD rpm_NN ._SENT After_IN incubation_NN ,_, bacteria_NNS were_VBD inoculated_VBN on_IN agar_NN plates_NNS ._SENT The_DT growth_NN rate_NN (_( percentage_NN of_IN control_NN )_) was_VBD calculated_VBN by_IN colony_NN counting_NN compared_VBN to_TO the_DT control_NN ._SENT Both_CC IgY-Hp_NP (_( 1_CD and_CC 10_CD mg/ml_NN )_) and_CC H._NP pylori_NNS (_( 108_CD CFU/ml_NP )_) were_VBD incubated_VBN at_IN 37oC_JJ under_IN 10_CD %_NN CO2_NN for_IN 6_CD h_NN at_IN 50_CD rpm_NN and_CC then_RB 50_CD mul_NN of_IN urea_NN base_NN (_( 2_CD %_NN urea-0.03_JJ %_NN phenol_NN red_NN )_) was_VBD added_VBN and_CC reacted_VBN for_IN 30_CD min_NN ._SENT Urease_NN activity_NN was_VBD measured_VBN by_IN a_DT spectrophotometer_NN at_IN 550_CD nm_NN and_CC is_VBZ represented_VBN as_IN a_DT percentage_NN of_IN the_DT control_NN ._SENT The_DT results_NNS are_VBP shown_VBN as_IN the_DT mean_JJ +-_NN SD_NN ._SENT *_SYM and_CC **_SYM ,_, statistically_RB significant_JJ differences_NNS from_IN the_DT values_NNS for_IN the_DT control_NN (_( P_NN <_SYM 0.05_CD and_CC P_NN <_SYM 0.01_CD ,_, respectively_RB )_) ._SENT FIG._NN 5_CD ._SENT |_SYM Effect_NN of_IN IgY-Hp_NP on_IN H._NP pylori_NNS Effect_NN of_IN IgY-Hp_NP on_IN H._NP pylori-induced_JJ gastric_JJ mucosal_JJ injury_NN ._SENT IgY-Hp_NP (_( 1_CD and_CC 10_CD mg/ml_NN )_) was_VBD orally_RB administered_VBN to_TO Mongolian_JJ gerbils_NNS for_IN 4_CD weeks_NNS ._SENT The_DT lymphocytes_NNS and_CC neutrophils_NNS were_VBD measured_VBN by_IN the_DT degree_NN of_IN lymphocyte_NN and_CC neutrophil_JJ infiltration_NN ,_, respectively_RB ._SENT The_DT results_NNS are_VBP shown_VBN as_IN the_DT mean_JJ +-_NN SD_NN ._SENT *_SYM ,_, statistically_RB significant_JJ differences_NNS from_IN the_DT values_NNS for_IN the_DT H._NP pylori_NNS infection_NN group_NN (_( P_NN <_SYM 0.01_CD )_) ._SENT FIG._NN 6_CD ._SENT |_SYM SEM_NP findings_NNS for_IN H._NP pylori_NNS SEM_NP findings_NNS for_IN H._NP pylori-infected_JJ AGS_NP cells_NNS in_IN the_DT presence_NN or_CC absence_NN of_IN IgY-Hp_NP ._SENT (_( A_NP )_) AGS_NP cells_NNS ._SENT (_( B_NP )_) AGS_NP cells_NNS infected_VBN with_IN H._NP pylori_NNS (_( 108_CD CFU/ml_NN )_) ._SENT (_( C_NP )_) AGS_NP cells_NNS infected_VBN with_IN H._NP pylori_NNS (_( 108_CD CFU/ml_NN )_) pretreated_VBN with_IN IgY-Hp_NP (_( 10_CD mg/ml_NN )_) ._SENT TABLE_NN 1_CD |_SYM Summary_NN of_IN yield_NN and_CC purity_NN of_IN IgY_NP from_IN egg_NN yolk_NN The_DT present_JJ study_NN demonstrates_VBZ that_IN IgY-Hp_NP prepared_VBN from_IN the_DT egg_NN yolk_NN of_IN hens_NNS immunized_VBN with_IN H._NP pylori_NNS is_VBZ effective_JJ in_IN the_DT treatment_NN of_IN H._NP pylori_NNS infections_NNS ._SENT H._NP pylori_NNS infections_NNS are_VBP widespread_JJ in_IN humans_NNS ,_, and_CC ,_, although_IN they_PP can_MD be_VB cured_VBN using_VBG antimicrobial_JJ therapy_NN ,_, this_DT large-scale_JJ use_NN of_IN antibiotics_NNS leads_VBZ to_TO the_DT emergence_NN of_IN antibiotic-resistant_JJ strains_NNS ._SENT Moreover_RB ,_, antimicrobial_JJ therapeutic_JJ cures_NNS of_IN H._NP pylori_NNS infections_NNS do_VBP not_RB lead_VB to_TO immunity_NN from_IN reinfection_NN ,_, and_CC the_DT emergence_NN of_IN antibiotic-resistant_JJ strains_NNS can_MD increase_VB failure-of-therapy_NN and_CC relapse_NN rates_NNS ._SENT Consequently_RB ,_, there_EX have_VBP been_VBN tremendous_JJ efforts_NNS to_TO seek_VB alternatives_NNS to_TO antibiotic-based_JJ therapies_NNS for_IN a_DT more_RBR widely_RB available_JJ means_NNS of_IN treating_VBG ,_, suppressing_VBG ,_, or_CC preventing_VBG H._NP pylori_NNS infections_NNS without_IN drug_NN resistance_NN problems_NNS ._SENT Recent_JJ work_NN in_IN several_JJ laboratories_NNS ,_, using_VBG several_JJ animal_NN models_NNS ,_, has_VBZ shown_VBN that_DT immunization_NN with_IN defined_VBN native_JJ and_CC recombinant_JJ antigens_NNS of_IN H._NP pylori_NNS can_MD protect_VB against_IN H._NP pylori_NNS infections_NNS ._SENT The_DT mechanisms_NNS of_IN protection_NN are_VBP still_RB poorly_RB understood_VBN ._SENT Although_IN prophylactic_JJ and_CC therapeutic_JJ immunization_NN has_VBZ been_VBN successful_JJ in_IN animal_JJ models_NNS ,_, efficacy_NN data_NNS for_IN humans_NNS are_VBP still_RB lacking_VBG ._SENT On_IN the_DT other_JJ hand_NN ,_, treatment_NN of_IN H._NP pylori_NNS infection_NN by_IN oral_JJ administration_NN of_IN active_JJ antibodies_NNS specific_JJ to_TO H._NP pylori_NNS may_MD have_VB merit_NN ,_, due_JJ to_TO the_DT antibody_NN being_VBG recognized_VBN by_IN H._NP pylori_NNS ,_, thus_RB inhibiting_VBG adhesion_NN of_IN the_DT bacterium_NN to_TO human_JJ epithelial_JJ cells_NNS more_RBR efficiently_RB ._SENT Many_JJ studies_NNS have_VBP shown_VBN that_IN egg_NN yolk_NN from_IN an_DT immunized_VBN hen_NN has_VBZ an_DT antibody_NN capable_JJ of_IN specific_JJ recognition_NN in_IN an_DT abundant_JJ quantity_NN and_CC is_VBZ therefore_RB economical_JJ ._SENT We_PP estimated_VBD that_IN 1_CD ml_NN of_IN the_DT egg_NN yolk_NN (_( 15_CD ml_NN per_IN egg_NN )_) contains_VBZ about_RB 9.4_CD mg_NN of_IN IgY_NP ._SENT A_DT hen_NN lays_VBZ about_RB 250_CD eggs_NNS (_( about_RB 4,000_CD ml_NN of_IN egg_NN yolk_NN )_) in_IN a_DT year_NN ;_: thus_RB ,_, the_DT eggs_NNS laid_VBN by_IN an_DT immunized_VBN hen_NN in_IN a_DT year_NN would_MD yield_VB 40_CD g_NN of_IN IgY_NP ._SENT Oral_JJ administration_NN of_IN IgY_NP from_IN chicken_NN egg_NN yolk_NN has_VBZ been_VBN used_VBN successfully_RB by_IN many_JJ researchers_NNS in_IN preventing_VBG many_JJ intestinal_JJ diseases_NNS ,_, such_JJ as_IN those_DT caused_VBN by_IN enterotoxigenic_JJ E._NP coli_NNS and_CC human_JJ rotavirus_NN ._SENT Sugita-Konishi_NP et_FW al._FW reported_VBD that_IN IgY_NP ,_, obtained_VBN from_IN hens_NNS immunized_VBN with_IN a_DT mixture_NN of_IN formalin-treated_JJ pathogenic_JJ bacteria_NNS ,_, inhibited_VBD the_DT growth_NN of_IN Pseudomonas_NP aeruginosa_NP ._SENT The_DT production_NN of_IN Staphylococcus_NP aureus_NN enterotoxin_NN A_DT and_CC adhesion_NN of_IN Salmonella_NP typhimurium_NN serovar_NN Enteritidis_NP to_TO cultured_JJ human_JJ intestinal_JJ cells_NNS were_VBD also_RB inhibited_VBN ._SENT IgY_NP antibodies_NNS inhibited_VBD the_DT colonization_NN of_IN teeth_NNS by_IN Streptococcus_NP mutans_NNS ,_, thus_RB preventing_VBG plaque_NN formation_NN in_IN humans_NNS ._SENT However_RB ,_, there_EX has_VBZ been_VBN no_DT report_NN so_RB far_RB on_IN the_DT use_NN of_IN IgY_NP in_IN the_DT prevention_NN and_CC treatment_NN of_IN H._NP pylori_NNS infections_NNS ._SENT In_IN this_DT study_NN ,_, IgY-Hp_NP ,_, obtained_VBN from_IN hens_NNS immunized_VBN with_IN H._NP pylori_NNS whole-cell_NN lysate_NN ,_, dramatically_RB inhibited_VBD the_DT growth_NN of_IN H._NP pylori_NNS in_IN vitro_NN ._SENT If_IN the_DT antibody_NN IgY_NP had_VBD no_DT specific_JJ effect_NN ,_, no_DT inhibition_NN of_IN bacterial_JJ growth_NN would_MD occur_VB ._SENT It_PP seems_VBZ clear_JJ from_IN our_PP$ observations_NNS ,_, using_VBG gerbil_NN models_NNS ,_, that_WDT IgY-Hp_NP decreased_VBD H._NP pylori-induced_JJ gastric_JJ mucosal_JJ injury_NN ,_, as_RB determined_VBN by_IN the_DT degree_NN of_IN lymphocyte_NN and_CC neutrophil_JJ infiltration_NN ._SENT Therefore_RB ,_, the_DT therapeutic_JJ value_NN of_IN orally_RB administered_VBN IgY-Hp_NP ,_, against_IN the_DT experimental_JJ model_NN in_IN gerbils_NNS ,_, lies_VBZ in_IN its_PP$ ability_NN to_TO inhibit_VB the_DT bacterial_JJ organism_NN ._SENT More_RBR convincing_JJ evidence_NN in_IN support_NN of_IN the_DT specificity_NN of_IN these_DT antibodies_NNS comes_VBZ from_IN inhibition_NN of_IN H._NP pylori_NNS attachment_NN to_TO AGS_NP cells_NNS ,_, as_RB confirmed_VBN by_IN SEM_NP ._SENT Although_IN the_DT mechanisms_NNS by_IN which_WDT IgY-Hp_NP prevented_VBD H._NP pylori_NNS colonization_NN are_VBP yet_RB not_RB elucidated_VBN ,_, our_PP$ results_NNS suggest_VBP that_IN IgY-Hp_NP would_MD inhibit_VB H._NP pylori_NNS adherence_NN properties_NNS ._SENT Of_IN interest_NN ,_, the_DT IgY-Hp_NP used_VBN in_IN this_DT study_NN significantly_RB inhibited_VBD urease_NN activity_NN ._SENT The_DT relationship_NN between_IN inhibitions_NNS of_IN urease_NN activity_NN and_CC adhesion_NN properties_NNS needs_VBZ to_TO be_VB clarified_VBN ._SENT In_IN this_DT study_NN ,_, IgY-Hp_NP seems_VBZ to_TO have_VB two_CD properties_NNS :_: inhibiting_VBG adhesion_NN of_IN the_DT bacterium_NN to_TO gastric_JJ epithelial_JJ cells_NNS and_CC demonstrating_VBG powerful_JJ urease-inhibiting_NN activity_NN ._SENT For_IN practical_JJ application_NN of_IN IgY-Hp_NP together_RB with_IN food_NN or_CC pharmaceutical_JJ materials_NNS to_TO treat_VB H._NP pylori_NNS infection_NN ,_, the_DT stability_NN of_IN IgY-Hp_NP toward_IN heat_NN ,_, acid_NN ,_, or_CC pepsin_NN was_VBD studied_VBN by_IN measuring_VBG the_DT remaining_VBG activity_NN by_IN ELISA_NP ._SENT Immunologically_RB ,_, IgY-Hp_NP stayed_VBD active_JJ at_IN 60C_JJ for_IN 10_CD min_NN ,_, suggesting_VBG that_IN pasteurization_NN can_MD be_VB applied_VBN to_TO sterilize_VB the_DT product_NN ._SENT The_DT fortification_NN of_IN food_NN products_NNS with_IN this_DT immunoglobulin_NN ,_, together_RB with_IN its_PP$ higher_JJR productivity_NN and_CC effectiveness_NN ,_, would_MD significantly_RB decrease_VB the_DT activities_NNS of_IN H._NP pylori_NNS infections_NNS ._SENT In_IN conclusion_NN ,_, the_DT encouraging_JJ results_NNS of_IN this_DT study_NN indicate_VBP that_IN the_DT IgY-Hp_NP obtained_VBD from_IN hens_NNS immunized_VBN by_IN H._NP pylori_NNS may_MD provide_VB a_DT novel_JJ approach_NN to_TO the_DT management_NN of_IN H._NP pylori_NNS infections_NNS in_IN humans_NNS ._SENT However_RB ,_, many_JJ problems_NNS remain_VBP unsolved_JJ for_IN the_DT clinical_JJ application_NN ,_, such_JJ as_IN the_DT effect_NN of_IN IgY-Hp_NP in_IN humans_NNS ,_, the_DT persistence_NN of_IN the_DT effect_NN of_IN IgY-Hp_NP after_IN cessation_NN of_IN the_DT application_NN ,_, and_CC the_DT potential_NN for_IN eradicating_VBG an_DT established_JJ infection_NN ._SENT 